Netarsudil
Rhopressa
NADAC/unit
$131.9200
No Shortage
Tier 1: 17.6%
PA Req: 0.6%
RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
vs. brand Rhopressa: Generic saves up to -1219% per unit
Generic Manufacturers
ALCON LABORATORIES INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.